Teva's Key Drugs in Its Specialty Products Pipeline
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | FiercePharma
Teva Pharmaceuticals Acquisition – PL Developments
EX-99.1
Teva Pharmaceuticals: Value Play or Value Trap? | by Shivam Kollur | Medium
FDA nods for Teva, J&J signal pipeline progress - MM+M - Medical Marketing and Media
Fresh from the biotech pipeline—2012 | Nature Biotechnology
Teva pharmaceutical industries limited
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
Producing Quality Products | Teva Pharmaceuticals
Pharm Exec's 2020 Pipeline Report
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
Drug pipeline: 4Q18 | Nature Biotechnology
Teva Pharmaceutical: Generic Market Access to Global Healthcare Industry | IntechOpen
The Teva Advantage
EX-99.1
Teva Pharmaceutical: Generic Market Access to Global Healthcare Industry | IntechOpen
Teva's drug pipeline could contain blockbusters - Globes
FDA approves first generic version of epilepsy drug Sabril from Teva
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
Anything but Generic: A map for Selling to Teva Pharmaceuticals
Teva-Takeda joint venture divests certain assets in Japan to Nichi-Iko - Pharmaceutical Technology
Celltrion FDA warning causes headache for Teva's biologics ambition
Sosei see Teva pipeline cull as an opportunity -
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
